NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zai Lab Limited (NASDAQ: ZLAB)

 
ZLAB Technical Analysis
5
As on 25th Jan 2022 ZLAB Share Price closed @ 48.14 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 141.36 & Strong Sell for SHORT-TERM with Stoploss of 97.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZLAB Share Price

Open 48.31 Change Price %
High 49.94 1 Day -1.72 -3.45
Low 45.81 1 Week -3.50 -6.78
Close 48.14 1 Month -17.37 -26.52
Volume 513561 1 Year -36.40 -43.06
52 Week High 191.71 | 52 Week Low 48.14
 
NASDAQ USA Most Active Stocks
XELA 0.55 34.15%
AAPL 159.78 -1.14%
AMD 111.13 -4.63%
SOFI 12.76 -4.06%
NVDA 223.24 -4.48%
MSFT 288.49 -2.66%
SNDL 0.48 4.35%
BBIG 3.01 2.73%
INTC 51.00 -1.81%
PIXY 1.55 -9.88%
 
NASDAQ USA Top Gainers Stocks
CETXW 0.02 100.00%
ZJZZT 37.50 79.86%
AKICW 0.77 60.42%
ZWZZT 22.00 46.67%
SRRA 22.68 46.23%
DBGIW 0.49 40.00%
APM 2.25 38.89%
APM 2.25 38.89%
APM 2.25 38.89%
APM 2.25 38.89%
 
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
DSKEW 0.01 -66.67%
IKNX 19.52 -42.42%
PAVMW 0.03 -40.00%
OTLKW 0.03 -40.00%
XBIOW 1.30 -35.00%
ROVRW 1.30 -34.34%
STMP 0.02 -33.33%
STMP 0.02 -33.33%
IMRNW 0.20 -33.33%
 
 
ZLAB
Daily Charts
ZLAB
Intraday Charts
Whats New @
Bazaartrend
ZLAB
Free Analysis
 
ZLAB Important Levels Intraday
RESISTANCE56.10
RESISTANCE53.55
RESISTANCE51.97
RESISTANCE50.39
SUPPORT45.89
SUPPORT44.31
SUPPORT42.73
SUPPORT40.18
 
ZLAB Target for Month January
4th UP TARGET137.63
3rd UP TARGET108.93
2nd UP TARGET91.19
1st UP TARGET73.45
1st DOWN TARGET22.83
2nd DOWN TARGET5.09
3rd DOWN TARGET-12.65
4th DOWN TARGET-41.35
 
ZLAB Weekly Target
4th UP TARGET66.50
3rd UP TARGET60.61
2nd UP TARGET56.97
1st UP TARGET53.33
1st DOWN TARGET42.95
2nd DOWN TARGET39.31
3rd DOWN TARGET35.67
4th DOWN TARGET29.78
 
ZLAB Target for Year 2022
4th UP TARGET335.44
3rd UP TARGET243.3
2nd UP TARGET186.35
1st UP TARGET129.39
1st DOWN TARGET-33.11
2nd DOWN TARGET-90.07
3rd DOWN TARGET-147.02
4th DOWN TARGET-239.16
 
 
ZLAB Other Details
Segment EQ
Market Capital 10020775936.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZLAB Address
ZLAB
 
ZLAB Latest News
 
Your Comments and Response on Zai Lab Limited
 
ZLAB Business Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; argenx BV; and Geneseeq Technology Inc. The company was incorporated in 2013 and is headquartered in Shanghai, China. Address: Jinchuang Plaza, Shanghai, China, 201210
 
2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service